share_log

Mangoceuticals | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Mangoceuticals | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Mangoceuticals | S-8:員工福利計劃證券登記
美股SEC公告 ·  05/14 09:04

Moomoo AI 已提取核心訊息

On May 14, 2024, Mangoceuticals, Inc., a Texas-based pharmaceutical company, filed a Form S-8 registration statement with the Securities and Exchange Commission (SEC). The filing is intended to register an additional 7,831,500 shares of common stock under the company's Amended and Restated 2022 Equity Incentive Plan. This move comes after an amendment to the plan that increased the number of shares reserved for issuance by 5,831,500, effective March 25, 2024, and an automatic increase of 2,000,000 shares effective April 1, 2024. The registration statement incorporates by reference several previously filed documents, including the company's Annual Report on Form 10-K for the year ended December 31, 2023, and various Current Reports on Form 8-K. The validity of the common stock covered by this prospectus has been passed upon by The Loev Law Firm, PC. The CEO and Chairman of Mangoceuticals, Jacob D. Cohen, along with other executives and directors, have signed the registration statement, affirming the company's compliance with the requirements for filing on Form S-8.
On May 14, 2024, Mangoceuticals, Inc., a Texas-based pharmaceutical company, filed a Form S-8 registration statement with the Securities and Exchange Commission (SEC). The filing is intended to register an additional 7,831,500 shares of common stock under the company's Amended and Restated 2022 Equity Incentive Plan. This move comes after an amendment to the plan that increased the number of shares reserved for issuance by 5,831,500, effective March 25, 2024, and an automatic increase of 2,000,000 shares effective April 1, 2024. The registration statement incorporates by reference several previously filed documents, including the company's Annual Report on Form 10-K for the year ended December 31, 2023, and various Current Reports on Form 8-K. The validity of the common stock covered by this prospectus has been passed upon by The Loev Law Firm, PC. The CEO and Chairman of Mangoceuticals, Jacob D. Cohen, along with other executives and directors, have signed the registration statement, affirming the company's compliance with the requirements for filing on Form S-8.
2024年5月14日,總部位於德克薩斯州的製藥公司Mangoceuticals, Inc. 向美國證券交易委員會(SEC)提交了S-8表格註冊聲明。該文件旨在根據公司經修訂和重述的2022年股權激勵計劃再註冊7,831,500股普通股。此舉是在對該計劃進行修正之後採取的,該修正案將預留髮行的股票數量增加了5,831,500股,自2024年3月25日起生效,自2024年4月1日起自動增加200萬股。註冊聲明以引用方式納入了先前提交的幾份文件,包括公司截至2023年12月31日止年度的10-K表年度報告以及表格8-K的各種最新報告。本招股說明書所涵蓋的普通股的有效性已由Loev Law Firm, PC.Mangoceuticals首席執行官兼董事長雅各布·科恩以及其他高管和董事簽署了註冊聲明,確認該公司遵守了提交S-8表格的要求。
2024年5月14日,總部位於德克薩斯州的製藥公司Mangoceuticals, Inc. 向美國證券交易委員會(SEC)提交了S-8表格註冊聲明。該文件旨在根據公司經修訂和重述的2022年股權激勵計劃再註冊7,831,500股普通股。此舉是在對該計劃進行修正之後採取的,該修正案將預留髮行的股票數量增加了5,831,500股,自2024年3月25日起生效,自2024年4月1日起自動增加200萬股。註冊聲明以引用方式納入了先前提交的幾份文件,包括公司截至2023年12月31日止年度的10-K表年度報告以及表格8-K的各種最新報告。本招股說明書所涵蓋的普通股的有效性已由Loev Law Firm, PC.Mangoceuticals首席執行官兼董事長雅各布·科恩以及其他高管和董事簽署了註冊聲明,確認該公司遵守了提交S-8表格的要求。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息